Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.

[1]  T. Roth,et al.  Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial. , 2015, Sleep medicine.

[2]  A. Krystal,et al.  Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. , 2013, Sleep medicine reviews.

[3]  E. Inada,et al.  Effects of mirtazapine on sleep disturbance under neuropathic pain‐like state , 2012, Synapse.

[4]  A. Krystal,et al.  Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. , 2011, Sleep.

[5]  T. Scammell,et al.  Sleep neurobiology from a clinical perspective. , 2011, Sleep.

[6]  J. Ramaekers,et al.  Residual effects of esmirtazapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype , 2011, Psychopharmacology.

[7]  S. Bolge,et al.  Burden of chronic sleep maintenance insomnia characterized by nighttime awakenings. , 2010, Population health management.

[8]  M. Fava,et al.  Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. , 2007, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[9]  T. Roth,et al.  Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia. , 2006, Sleep medicine.

[10]  T. Roth,et al.  Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia , 2004, Current medical research and opinion.

[11]  S. Aslan,et al.  The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. , 2002, Sleep.

[12]  L. Tuomisto,et al.  Modifying effects of histamine on circadian rhythms and neuronal excitability , 2001, Behavioural Brain Research.

[13]  M. Sateia,et al.  Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study , 2000, Biological Psychiatry.

[14]  J. Fawcett,et al.  Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. , 1998, Journal of affective disorders.

[15]  T. Boer.  The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. , 1995 .

[16]  B. Bjorvatn,et al.  Effects of the selective 5‐HT1B agonist, CGS 12066B, on sleep/waking stages and EEG power spectrum in rats , 1994, Journal of sleep research.

[17]  J. Monti,et al.  The effects of selective activation of the 5-HT3 receptor with m-chlorophenylbiguanide on sleep and wakefulness in the rat. , 1993, European journal of pharmacology.

[18]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[19]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[20]  Tien-Chun Li,et al.  Rapid weight gain during mirtazapine treatment. , 2011, The Journal of neuropsychiatry and clinical neurosciences.

[21]  R. Rosenberg.  Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. , 2006, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[22]  J. Leysen,et al.  Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat , 2004, Psychopharmacology.

[23]  G. Ruigt,et al.  Characteristic Effects of Mirtazapine and Other Antidepressants on Rat Sleep EEG , 1996, European Psychiatry.

[24]  G. Ruigt,et al.  Clinical Implications of the Adrenergenic and Serotonergenic Receptor Binding Profile of the New Antidepressant Mirtazapine , 1996, European Psychiatry.